152 related articles for article (PubMed ID: 8673714)
21. Paramagnetic pharmaceuticals for magnetic resonance imaging.
Wesbey GE; Engelstad BL; Brasch RC
Physiol Chem Phys Med NMR; 1984; 16(2):145-55. PubMed ID: 6095341
[TBL] [Abstract][Full Text] [Related]
22. Liver MRI with contrast enhancement.
Runge VM
Crit Rev Diagn Imaging; 1997 Jun; 38(3):207-30. PubMed ID: 9226107
[TBL] [Abstract][Full Text] [Related]
23. Contrast agents and temporal resolution in breast MR imaging.
Sardanelli F; Iozzelli A; Fausto A
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):69-75. PubMed ID: 12585658
[TBL] [Abstract][Full Text] [Related]
24. Intraluminal contrast agents for MR imaging of the abdomen and pelvis.
Pels Rijcken TH; Davis MA; Ros PR
J Magn Reson Imaging; 1994; 4(3):291-300. PubMed ID: 8061424
[TBL] [Abstract][Full Text] [Related]
25. Characterization and molecular detection of atherothrombosis by magnetic resonance--potential tools for individual risk assessment and diagnostics.
Ala-Korpela M; Sipola P; Kaski K
Ann Med; 2006; 38(5):322-36. PubMed ID: 16938802
[TBL] [Abstract][Full Text] [Related]
26. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
Mohs AM; Lu ZR
Expert Opin Drug Deliv; 2007 Mar; 4(2):149-64. PubMed ID: 17335412
[TBL] [Abstract][Full Text] [Related]
27. Molecular magnetic resonance imaging with targeted contrast agents.
Artemov D
J Cell Biochem; 2003 Oct; 90(3):518-24. PubMed ID: 14523986
[TBL] [Abstract][Full Text] [Related]
28. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of alternative oral contrast agents for MRI of the gastrointestinal tract.
Babos M; Schwarcz A; Randhawa MS; Marton B; Kardos L; Palkó A
Eur J Radiol; 2008 Jan; 65(1):133-9. PubMed ID: 17485189
[TBL] [Abstract][Full Text] [Related]
30. Gadolinium-based magnetic resonance imaging contrast agents in interventional radiology.
Atar E
Isr Med Assoc J; 2004 Jul; 6(7):412-4. PubMed ID: 15274532
[TBL] [Abstract][Full Text] [Related]
31. [Optimization of dosage and exam technique in the use of oral contrast media in magnetic resonance].
Broglia L; Tortora A; Maccioni F; Arpesani R; Marcelli G; Ascarelli A; Rossi P
Radiol Med; 1999 May; 97(5):365-70. PubMed ID: 10432968
[TBL] [Abstract][Full Text] [Related]
32. Detection and characterization of hepatocellular carcinoma in rats with liver cirrhosis: diagnostic value of combined use of MR positive and negative contrast agents.
Guo DM; Qiu TS; Bian J; Liu SF; Wang CZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):65-70. PubMed ID: 19208518
[TBL] [Abstract][Full Text] [Related]
33. [Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media].
Mohr U; Weissleder R
Z Lymphol; 1996 Jun; 20(1):15-20. PubMed ID: 8768044
[TBL] [Abstract][Full Text] [Related]
34. MR imaging of the small bowel.
Fidler J
Radiol Clin North Am; 2007 Mar; 45(2):317-31. PubMed ID: 17502220
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes.
Briley-Saebo KC; Mulder WJ; Mani V; Hyafil F; Amirbekian V; Aguinaldo JG; Fisher EA; Fayad ZA
J Magn Reson Imaging; 2007 Sep; 26(3):460-79. PubMed ID: 17729343
[TBL] [Abstract][Full Text] [Related]
36. Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs).
Querol M; Bogdanov A
J Magn Reson Imaging; 2006 Nov; 24(5):971-82. PubMed ID: 17024658
[TBL] [Abstract][Full Text] [Related]
37. Ferric ammonium citrate as a positive bowel contrast agent for MR imaging of the upper abdomen. Safety and diagnostic efficacy.
Kivelitz D; Gehl HB; Heuck A; Krahe T; Taupitz M; Lodemann KP; Hamm B
Acta Radiol; 1999 Jul; 40(4):429-35. PubMed ID: 10394873
[TBL] [Abstract][Full Text] [Related]
38. Contrast-enhanced MR imaging of the pancreas.
Kettritz U; Semelka RC
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):87-100. PubMed ID: 8673719
[TBL] [Abstract][Full Text] [Related]
39. Blackberry (Rubus spp.): a pH-dependent oral contrast medium for gastrointestinal tract images by magnetic resonance imaging.
Espinosa MG; Sosa M; De León-Rodríguez LM; Córdova T; Bernal-Alvarado J; Avila-Rodríguez M; Reyes-Aguilera JA; Ortíz JJ; Barrios FA
Magn Reson Imaging; 2006 Feb; 24(2):195-200. PubMed ID: 16455409
[TBL] [Abstract][Full Text] [Related]
40. New MR imaging contrast agents.
Earls JP; Bluemke DA
Magn Reson Imaging Clin N Am; 1999 May; 7(2):255-73. PubMed ID: 10382160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
